Johnson & Johnson (JNJ)
| Market Cap | 611.07B +66.6% |
| Revenue (ttm) | 97.93B +8.1% |
| Net Income | 21.04B -7.2% |
| EPS | 8.63 -7.7% |
| Shares Out | 2.41B |
| PE Ratio | 29.40 |
| Forward PE | 21.02 |
| Dividend | $5.36 (2.11%) |
| Ex-Dividend Date | May 26, 2026 |
| Volume | 8,770,553 |
| Open | 255.53 |
| Previous Close | 257.77 |
| Day's Range | 252.14 - 256.39 |
| 52-Week Range | 154.80 - 269.43 |
| Beta | 0.23 |
| Analysts | Buy |
| Price Target | 262.27 (+3.32%) |
| Earnings Date | Jul 15, 2026 |
About JNJ
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription... [Read more]
Financial Performance
In 2025, Johnson & Johnson's revenue was $94.19 billion, an increase of 6.05% compared to the previous year's $88.82 billion. Earnings were $26.80 billion, an increase of 90.56%.
Financial StatementsAnalyst Summary
According to 23 analysts, the average rating for JNJ stock is "Buy." The 12-month stock price target is $262.27, which is an increase of 3.32% from the latest price.
News
5 Things to Know Before the Stock Market Opens on Wednesday
Stock futures are pointing to a higher open as investors digest a flurry of earnings reports from major companies; oil prices are higher as the U.S. and Iran continue to trade strikes; PayPal shares a...
Johnson & Johnson says capital allocation priorities remain unchanged
Says expects to return cash to shareholders mainly through the dividend.
Johnson & Johnson says confident in long term projections of Medtech business
08:54 EDT Johnson & Johnson says confident in long term projections of Medtech business
Johnson & Johnson says has strongest portfolio, pipeline in company’s history
Says pleased with progress of new launches. Expects momentum to accelerate into 2027 and beyond. Says on track to be number one oncology company by 2030. Says confidence rooted in…
Johnson & Johnson Slides: Q2 2026
Johnson & Johnson has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 15, 2026.
Johnson & Johnson Earnings release: Q2 2026
Johnson & Johnson released its Q2 2026 earnings on July 15, 2026, summarizing the period's financial results.
ASML, Intel, Johnson & Johnson, and More Stocks That Explain Today's Market
Stocks look set to build on their recent gains as investors try to make sense of another batch of quarterly earnings reports.
Johnson & Johnson Hikes Guidance, Stock Falls
The drugmaker posts earnings that narrowly beat expectations and raises its full-year outlook.
Johnson & Johnson Bumps Up Guidance as Sales Rise
The drug and medical-device maker raised its forecast for the year after recording higher sales in the second quarter.
Johnson & Johnson reports Q2 adjusted EPS $2.90, consensus $2.85
Reports Q2 revenue $25.31B, consensus $25.06B. “Johnson & Johnson delivered strong second-quarter results, demonstrating the power of our innovation, the depth of our portfolio and the momentum in our...
Johnson & Johnson raises FY26 adjusted EPS view to $11.60-$11.75
Prior view was $11.45-$11.65, consensus $11.58. Raises FY26 estimated reported revenue view to $100.8B-$101.4B from $100.3B-$101.3B, consensus $101.06B.
Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2026 of $1.34 per share on the com...
J&J quarterly earnings beat Wall Street estimates on strength of medicines unit
Johnson & Johnson beat Wall Street estimates for second-quarter sales and profit on Wednesday, as strong growth from immunology drug Tremfya and cancer blockbuster Darzalex more than offset erosion ...
Johnson & Johnson reports Q2 2026 results, raises 2026 outlook
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2026. “Johnson & Johnson delivered strong second-quarter results, demonstrating the power...
Polymarket Odds: Will UAL, JNJ, MS Beat Earnings Tomorrow?
On Wednesday, July 15, United Airlines ($UAL), Johnson & Johnson ($JNJ), and Morgan Stanley ($MS) will report their earnings. Johnson & Johnson and Morgan Stanley will report before the market…
Johnson & Johnson Reports Q2 Earnings Tomorrow. What Investors Should Expect.
Healthcare products group Johnson & Johnson ($JNJ) reports Q2 earnings this week – July 15. Its shares are up 25% in the year-to-date, helped by demand for its cardiovascular products,…
Johnson & Johnson price target raised to $287 from $265 at RBC Capital
RBC Capital raised the firm’s price target on Johnson & Johnson to $287 from $265 and keeps an Outperform rating on the shares as part of a broader research note…
Johnson & Johnson price target raised to $300 from $250 at TD Cowen
TD Cowen raised the firm’s price target on Johnson & Johnson to $300 from $250 and keeps a Buy rating on the shares. The firm adjusted targets in the pharma…
Is Dividend King Johnson & Johnson (JNJ) a Buy Ahead of Earnings?
Johnson & Johnson ($JNJ) is scheduled to report its fiscal second-quarter results before the market opens on July 15. JNJ stock is a “Dividend King” because it has increased its…
Johnson & Johnson price target raised to $263 from $254 at BofA
BofA raised the firm’s price target on Johnson & Johnson to $263 from $254 and keeps a Neutral rating on the shares. Second quarter results are expected to highlight stronger…
3 ‘Strong Buy’ Dividend Aristocrat Stocks, According to Top Analysts — July 9, 2026
Johnson & Johnson ($JNJ), Chevron ($CVX), and Cintas ($CTAS) are three Dividend Aristocrat stocks with a Strong Buy rating on Wall Street, according to TipRanks’ Dividend Aristocrat tool. Dividend Ari...
The Big 3: UNH, KO, JNJ
For today's Big 3, Dan Deming turns to three stocks he sees fitting the theme of a broadening market as investors rotate out of AI and offer strength for other sectors. He explains why he sees opportu...
Johnson & Johnson announces FDA approval for THERMOCOOL SMARTTOUCH SF
Johnson & Johnson announced that the U.S. Food and Drug Administration approved the Dual Energy THERMOCOOL SMARTTOUCH SF Platform, an integrated catheter ablation solution that enables electrophysiolo...
Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform
IRVINE, Calif.--(BUSINESS WIRE)--Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform.
Jim Cramer says these are the 5 stocks to buy during this market rotation
CNBC's Jim Cramer said investors should use the latest market rotation as an opportunity to buy high-quality companies that were swept lower by broad institutional selling. He highlighted Johnson & Jo...